Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Nutrients ; 14(19)2022 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-36235796

RESUMEN

OBJECTIVE: Emotional eating (EE) is prevalent in people seeking obesity treatment and is a contributor to poor weight loss outcomes. We aimed to delineate the emotions most associated with this type of eating, and whether they differ by sex in people undergoing obesity treatment. METHODS: A cross-sectional study recruiting 387 adults from a hospital obesity management service. Emotional eating was measured using the Emotional Eating Scale (EES). Separate analyses included all participants, and those undergoing lifestyle interventions alone or in combination with obesity medication and/or bariatric surgery. RESULTS: A total of 387 people (71% women) participated in the study (n = 187 receiving lifestyle modification alone; n = 200 in combination with additional treatments). Feeling 'bored' was most commonly and most strongly associated with the urge to eat, regardless of sex or treatment. Women had higher scores for total EES, for subscales of depression and anger, and individual feelings of 'blue', 'sad' and 'upset' compared to men. CONCLUSIONS: Understanding why certain emotions differentially trigger an urge to eat in men and women, and finding strategies to break the link between boredom and eating may enable better personalisation of lifestyle interventions for people with obesity.


Asunto(s)
Ingestión de Alimentos , Conducta Alimentaria , Adulto , Estudios Transversales , Ingestión de Alimentos/psicología , Emociones , Conducta Alimentaria/psicología , Femenino , Humanos , Masculino , Obesidad/psicología , Obesidad/terapia , Encuestas y Cuestionarios
2.
Rev Endocr Metab Disord ; 23(4): 733-751, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-34851508

RESUMEN

Bariatric surgery results in long-term weight loss and an improved metabolic phenotype due to changes in the gut-brain axis regulating appetite and glycaemia. Neuroendocrine alterations associated with bariatric surgery may also influence hedonic aspects of eating by inducing changes in taste preferences and central reward reactivity towards palatable food. However, the impact of bariatric surgery on disordered eating behaviours (e.g.: binge eating, loss-of-control eating, emotional eating and 'addictive eating'), which are commonly present in people with obesity are not well understood. Increasing evidence suggests gut-derived signals, such as appetitive hormones, bile acid profiles, microbiota concentrations and associated neuromodulatory metabolites, can influence pathways in the brain implicated in food intake, including brain areas involved in sensorimotor, reward-motivational, emotional-arousal and executive control components of food intake. As disordered eating prevalence is a key mediator of weight-loss success and patient well-being after bariatric surgery, understanding how changes in the gut-brain axis contribute to disordered eating incidence and severity after bariatric surgery is crucial to better improve treatment outcomes in people with obesity.


Asunto(s)
Cirugía Bariátrica , Trastornos de Alimentación y de la Ingestión de Alimentos , Encéfalo , Ingestión de Alimentos , Conducta Alimentaria/fisiología , Humanos , Obesidad/cirugía , Pérdida de Peso/fisiología
3.
Nat Rev Endocrinol ; 17(9): 549-559, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34262156

RESUMEN

Bariatric surgery induces sustained weight loss and metabolic benefits via notable effects on the gut-brain axis that lead to alterations in the neuroendocrine regulation of appetite and glycaemia. However, in a subset of patients, bariatric surgery is associated with adverse effects on mental health, including increased risk of suicide or self-harm as well as the emergence of depression and substance use disorders. The contributing factors behind these adverse effects are not well understood. Accumulating evidence indicates that there are important links between gut-derived hormones, microbial and bile acid profiles, and disorders of mood and substance use, which warrant further exploration in the context of changes in gut-brain signalling after bariatric surgery. Understanding the basis of these adverse effects is essential in order to optimize the health and well-being of people undergoing treatment for obesity.


Asunto(s)
Cirugía Bariátrica/efectos adversos , Encéfalo/fisiología , Intestinos/fisiología , Trastornos Mentales/etiología , Apetito/fisiología , Cirugía Bariátrica/estadística & datos numéricos , Comunicación Celular/fisiología , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/cirugía , Hormonas Gastrointestinales/fisiología , Humanos , Trastornos Mentales/epidemiología , Sistemas Neurosecretores/fisiología , Obesidad/epidemiología , Obesidad/cirugía , Resultado del Tratamiento
4.
Artículo en Inglés | MEDLINE | ID: mdl-33741445

RESUMEN

Stress and low mood are powerful triggers for compulsive overeating, a maladaptive form of eating leading to negative physical and mental health consequences. Stress-vulnerable individuals, such as people with obesity, are particularly prone to overconsumption of high energy foods and may use it as a coping mechanism for general life stressors. Recent advances in the treatment of obesity and related co-morbidities have focused on the therapeutic potential of anorexigenic gut hormones, such as glucagon-like peptide 1 (GLP-1), which acts both peripherally and centrally to reduce energy intake. Besides its appetite suppressing effect, GLP-1 acts on areas of the brain involved in stress response and emotion regulation. However, the role of GLP-1 in emotion and stress regulation, and whether it is a viable treatment for stress-induced compulsive overeating, has yet to be established. A thorough review of the pre-clinical literature measuring markers of stress, anxiety and mood after GLP-1 exposure points to potential divergent effects based on temporality. Specifically, acute GLP-1 injection consistently stimulates the physiological stress response in rodents whereas long-term exposure indicates anxiolytic and anti-depressive benefits. However, the limited clinical evidence is not as clear cut. While prolonged GLP-1 analogue treatment in people with type 2 diabetes improved measures of mood and general psychological wellbeing, the mechanisms underlying this may be confounded by associated weight loss and improved blood glucose control. There is a paucity of longitudinal clinical literature on mechanistic pathways by which stress influences eating behavior and how centrally-acting gut hormones such as GLP-1, can modify these. (250).


Asunto(s)
Afecto/efectos de los fármacos , Emociones/efectos de los fármacos , Péptido 1 Similar al Glucagón/análogos & derivados , Péptido 1 Similar al Glucagón/administración & dosificación , Hiperfagia/tratamiento farmacológico , Estrés Psicológico/tratamiento farmacológico , Afecto/fisiología , Animales , Fármacos Antiobesidad/administración & dosificación , Eje Cerebro-Intestino/efectos de los fármacos , Eje Cerebro-Intestino/fisiología , Ensayos Clínicos Fase III como Asunto/métodos , Emociones/fisiología , Exenatida/administración & dosificación , Humanos , Hiperfagia/metabolismo , Hiperfagia/psicología , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Obesidad/psicología , Estrés Psicológico/metabolismo , Estrés Psicológico/psicología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA